Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 9, 17-26, January 1, 1949]
© 1949 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Movitz, D.
Right arrow Articles by Strauss, A. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Movitz, D.
Right arrow Articles by Strauss, A. A.

Effects of an Antireticular Cytotoxic Serum on the Brown-Pearce Carcinoma of the Rabbit*

David Movitz, M.D.{dagger}, Otto Saphir, M.D. and Alfred A. Strauss, M.D.

(From the Department of Pathology, Michael Reese Hospital, {ddagger} Chicago 16, Illinois)

Administration of a reticulo-endothelial tissue antiserum, previously known to affect reticulo-endothelial tissue directly by in vitro tissue culture, was followed by definite effects on the degree of malignancy of the Brown-Pearce carcinoma in vivo. Reticulo-endothelial cytotoxic serum may be given in doses that apparently produce stimulation instead of a cytotoxic effect. The cytotoxic effect of the serum on the Brown-Pearce carcinoma was indirectly and presumably well demonstrated in the first three series by producing definitely enhanced malignancy. A dose too minute to have an effect was observed in Series V and VI. Finally, a mild cytostimulatory effect was obtained with one-tenth the cytotoxic dose, given at 7- to 10-day intervals, as indirectly indicated by the resulting tumor inhibition.

* Aided by a grant from the Simon Schiff Fund.

{dagger} Ira Frank Research Fellow in pathology.

{ddagger} This department is in part supported by the Michael Reese Research Foundation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1949 by the American Association for Cancer Research.